Home Research

Academic Excellence

Peer-reviewed contributions to oncology literature and international clinical trials.

Knowledge Sharing

Peer-Reviewed Publications

18 original research articles and case reports in indexed international journals.

18

Jain AK, Parikh P, Dadhich SC, Arora A, Kumar M, Ranjan P, et al. Familial Polyposis and Colon Cancer. South Asian J Cancer 2024;13:305–8.

PubMed CentralDOAJ Indexed
17

Jain AK. Oral Cancer Screening: Insights into Epidemiology, Risk Factors, and Screening Programs for Improved Early Detection. Cancer Screen Prev 2024;3(2):97-105.

Google Scholar Indexed
16

Jain AK. Locally Advanced Breast Cancer: Response Evaluation to Neoadjuvant Chemotherapy by Clinico-Histopathological parameters and molecular imaging. Indian J. Surg. Oncol. 2023;14:279-87.

Scopus Indexed
15

Jain AK. Oncological Emergencies. In: Richhariya D, editor. Text Book of Emergency Medicine including intensive care & Trauma, 2nd ed. New Delhi: Jaypee brothers medical publishers; 2022. p. 967-78.

Book ChapterJaypee
14

Nair RR, Singh PK, Sharma J, Gambhir I, Khanna S, Jain AK, et al. An Unusual Case of Pancytopenia: Lessons Learnt. Indian J Crit Care Med 2022;26(1):141–4.

PubMed CentralEmbaseScopus Indexed
13

Jain AK, Bhat G, Gupta VG, Goyal H. Liquid Biopsy. Indian J Med Paediatr Oncol 2021;42: 77-9.

Scopus Indexed
12

Goyal H, Khetarpal A, Jain AK. A case of accidental vincristine overdose and effective use of therapeutic plasma exchange in its management. Indian J Med Paediatr Oncol 2020;41:770-2.

Scopus Indexed
11

Bhat G, Jain AK. Next generation sequencing. Indian J Med Paediatr Oncol 2020;41:381-2.

Scopus Indexed
10

Jain AK, Nandy P. Breast cancer prevention and management: Evidence and possibility in India. Muller J Med Sci Res 2019;10:33-5.

DOAJ Indexed
9

Jain AK, Nandy P. Clinico-Etiological Profile of Hyponatremia among Elderly Age Group Patients in a Tertiary Care Hospital in Sikkim. J Family Med Prim Care 2019;8:988-94.

PubMed Central Indexed
8

Rishi, Jain AK, Nandy P. Study of clinical, laboratory, and upper gastrointestinal endoscopic profile in patients of alcoholic liver disease in Sikkim. Med J DY Patil Vidyapeeth 2018;11:228-31.

DOAJ Indexed
7

Jain AK, Khatri D, Theengh DP, Nandy P. Clinico-epidemiological profile of haemodialysis patients in a teaching hospital in North Eastern India. Int J Sci Res 2018;7:15-8.

Indian Citation IndexIndex Medicus
6

Theengh DP, Yadav P, Jain AK, Nandy P. Assessment of metabolic syndrome in HIV infected individuals. Indian J Sex Transm Dis 2017;38:152-6.

PubMed Central Indexed
5

Lepcha LS, Jain AK, Nandy P. Sociodemographic profile and treatment outcome of tuberculosis patients registered under directly observed treatment short course in East Sikkim with reference to defaulters. J Med Soc 2017;31:147-51.

Embase Indexed
4

Suresh M, Srivastava NK, Jain AK, Nandy P. Thyroid dysfunction in critically ill patients in a tertiary care hospital in Sikkim. Thyroid Res Pract 2017; 14(2):58-62.

Index Copernicus Indexed
3

Gupta S, Jain AK, Khandelwal B, Nandy P. Case of New Onset Bochdalek’s Hernia in Adult: Is it Thalidomide Induced? Indian J Emerg Med 2016; 2(2):141-3.

Index Copernicus Indexed
2

Jain AK, Nandy P. A Solitary Anthracotic Lower Lobe Lung Mass Mimicking Lung Malignancy – An Unusual Presentation. Egypt J Bronchol 2016;10(2):82.

Google Scholar Indexed
1

Sinha R, Jain AK, Jagdhane N, Nandy P, Khanna SK. Moyamoya Disease Associated with Recurrent Right Thalamic Haemorrhage and Hydrocephalous: A Case Report. Turk Neurosurg 2014; 25(5): 811-3.

Medline Indexed
Academic Presence

Conference Papers & Posters

VII

Locally Advanced Breast Cancer: Response Evaluation to Neoadjuvant Chemotherapy by Clinico-Histopathological parameters and molecular imaging.

ISMPOCON 2020, Bengaluru
VI

A case of accidental vincristine overdose and effective use of therapeutic plasma exchange in its management.

ISMPOCON 2020, Bengaluru
V

Prevalence of Microsatellite Instability among Gastrointestinal and Hepato-Pancreato-Biliary cancers at a tertiary care hospital in North India.

ICON 2018, Indore
IV

Study of clinico-epidemiological profile of haemodialysis patients in a tertiary care university hospital in North Eastern India.

ISNCON 2015, Bengaluru
III

Mushroom poisoning in Sikkim: A retrospective study.

APICON 2015, Gurgaon
II

Thyroid dysfunction in critically ill patients in a tertiary care hospital in Sikkim.

EZ-APICON 2014, Guwahati
I

Clinico-Etiological Profile of Hyponatremia among Elderly Age Group Patients in a Tertiary Care Hospital in Sikkim.

IACMCON 2014, Siliguri
Excellence

Awards & Achievements

Second Place, Paper Presentation

West Bengal chapter of IACMCON – 2014, Siliguri.

Global Research

Clinical Trials

Dr. Jain has participated in 21 Phase III/IV international clinical trials.

Breast Oncology

  • Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in combination with weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer. Sub-Investigator
  • Phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane. Sub-Investigator
  • Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer. Sub-Investigator
  • Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of TX05 With Herceptin® in Subjects With HER2 Positive Early Breast Cancer. Sub-Investigator
  • Phase III Trial Assessing the Efficacy and Safety of Capivasertib + Paclitaxel as First-line Treatment for Patients with Locally Advanced or Metastatic TNBC (CapItello290). Sub-Investigator
  • Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in High Risk, Node Positive, Early Stage BC (MonarchE). Sub-Investigator
  • Phase III Study Evaluating the Efficacy and Safety of adjuvant Giredestrant compared with Physician's Choice of Adjuvant Endocrine Monotherapy in ER+/HER2- Early BC (lidERA). Sub-Investigator

Lung & Respiratory

  • Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC). Sub-Investigator
  • Phase III Global Study of MEDI4736 in Combination with Tremelimumab Versus Standard Platinum-Based Chemotherapy in First-Line Treatment of Advanced NSCLC (NEPTUNE). Sub-Investigator
  • Phase 3 Study of Lorlatinib monotherapy versus Crizotinib monotherapy in the first-line treatment of patients with advanced ALK-positive NSCLC. Sub-Investigator
  • Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with PD-L1 positive Non-small Cell Lung Cancer in India (Keynote-593). Sub-Investigator
  • Phase III Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive NSCLC (LAURA). Sub-Investigator
  • Phase III Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN). Sub-Investigator
  • Phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant NSCLC (KontRASt-02). Sub-Investigator

GI & Genitourinary

  • Comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC). Sub-Investigator
  • Open Label, Safety Study of Atezolizumab In Locally Advanced Or Metastatic Urothelial Or Non-Urothelial Carcinoma Of The Urinary Tract. Sub-Investigator
  • Phase III Study of Durvalumab and Tremelimumab as first-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA). Sub-Investigator
  • Phase III Study of First-Line Durvalumab + Tremelimumab + SOC Chemotherapy Versus Standard of Care Alone in Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE). Sub-Investigator

Gynae & Others

  • Phase III Global Study of MEDI4736 + Tremelimumab versus Standard of Care in First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients. Sub-Investigator
  • Phase III Study to Determine the Efficacy and Safety of Durvalumab following Chemoradiotherapy in Women With Locally Advanced Cervical Cancer (CALLA). Sub-Investigator
  • Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma in India (Keynote-593). Sub-Investigator
  • Phase 3 Study comparing Chemo-Immunotherapy versus Chemotherapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (FLORA-5). Sub-Investigator
  • IIS study for evaluation of efficacy and safety of Levonadifloxacin for Gram-Positive Bacterial Infection in Immunocompromised patients. Sub-Investigator

Innovation for Patients

Harnessing global research to provide tomorrow's treatments today.

Book Appointment Explore Expertise